<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37834128</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>19</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Role of Adipokines in the Pathologies of the Central Nervous System.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">14684</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241914684</ELocationID><Abstract><AbstractText>Adipokines are protein hormones secreted by adipose tissue in response to disruptions in physiological homeostasis within the body's systems. The regulatory functions of adipokines within the central nervous system (CNS) are multifaceted and intricate, and they have been identified in a number of pathologies. Therefore, specific adipokines have the potential to be used as biomarkers for screening purposes in neurological dysfunctions. The systematic review presented herein focuses on the analysis of the functions of various adipokines in the pathogenesis of CNS diseases. Thirteen proteins were selected for analysis through scientific databases. It was found that these proteins can be identified within the cerebrospinal fluid either by their ability to modify their molecular complex and cross the blood-brain barrier or by being endogenously produced within the CNS itself. As a result, this can correlate with their measurability during pathological processes, including Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, depression, or brain tumors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Korbinian</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0006-2757-8058</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Infectious Diseases, Medical University of Bialystok, Waszyngtona 17, 15-274 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szerenos</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0005-3334-391X</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Infectious Diseases, Medical University of Bialystok, Waszyngtona 17, 15-274 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>Dawid</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatric Infectious Diseases, Medical University of Bialystok, Waszyngtona 17, 15-274 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toczylowski</LastName><ForeName>Kacper</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0309-6987</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Infectious Diseases, Medical University of Bialystok, Waszyngtona 17, 15-274 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulik</LastName><ForeName>Artur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8391-4793</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Infectious Diseases, Medical University of Bialystok, Waszyngtona 17, 15-274 Bialystok, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054392">Adipokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054392" MajorTopicYN="N">Adipokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">adipokines</Keyword><Keyword MajorTopicYN="N">adipose tissue</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">encephalitis</Keyword><Keyword MajorTopicYN="N">meningitis</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurological dysfunctions</Keyword><Keyword MajorTopicYN="N">protein hormones</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37834128</ArticleId><ArticleId IdType="pmc">PMC10572192</ArticleId><ArticleId IdType="doi">10.3390/ijms241914684</ArticleId><ArticleId IdType="pii">ijms241914684</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ndjole A.M., Bodolea C., Nilsen T., Gordh T., Flodin M., Larsson A. Determination of Cerebrospinal Fluid Cystatin C on Architect Ci8200. J. Immunol. Methods. 2010;360:84&#x2013;88. doi: 10.1016/j.jim.2010.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2010.06.012</ArticleId><ArticleId IdType="pubmed">20598708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako W., Ishimoto S. Can Cystatin C in Cerebrospinal Fluid Be a Biomarker for Amyotrophic Lateral Sclerosis? A Lesson from Previous Studies. Neurol. Clin. Neurosci. 2014;2:72&#x2013;75. doi: 10.1111/ncn3.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ncn3.82</ArticleId></ArticleIdList></Reference><Reference><Citation>Delanaye P., Glassock R.J. Lifetime Risk of CKD: What Does It Really Mean? Clin. J. Am. Soc. Nephrol. 2015;10:1504&#x2013;1506. doi: 10.2215/CJN.07860715.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.07860715</ArticleId><ArticleId IdType="pmc">PMC4559513</ArticleId><ArticleId IdType="pubmed">26286926</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlois V. Laboratory Evaluation at Different Ages. In: Geary D.F., Schaefer F., editors. Comprehensive Pediatric Nephrology. Elsevier; Amsterdam, The Netherlands: 2008. pp. 39&#x2013;54.</Citation></Reference><Reference><Citation>Chuma M., Kondo M., Zamami Y., Takechi K., Goda M., Okada N., Shibata A., Asada M., Oto J., Yanagawa H., et al. Successful Vancomycin Dose Adjustment in a Sepsis Patient with Bacterial Meningitis Using Cystatin C. Acta Med. Okayama. 2020;74:365&#x2013;370. doi: 10.18926/AMO/60376.</Citation><ArticleIdList><ArticleId IdType="doi">10.18926/AMO/60376</ArticleId><ArticleId IdType="pubmed">32843769</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Xu J., Chang L., Miao Z., Heang D., Pu Y., Zhou X., Zhang L., Xie H. Cystatin C Improves Blood&#x2013;Brain Barrier Integrity after Ischemic Brain Injury in Mice. J. Neurochem. 2020;153:413&#x2013;425. doi: 10.1111/jnc.14894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14894</ArticleId><ArticleId IdType="pubmed">31603990</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoghooghi V., Palmer A.L., Frederick A., Jiang Y., Merkens J.E., Balakrishnan A., Finlay T.M., Grubb A., Levy E., Gordon P., et al. Cystatin C Plays a Sex-Dependent Detrimental Role in Experimental Autoimmune Encephalomyelitis. Cell Rep. 2020;33:108236. doi: 10.1016/j.celrep.2020.108236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108236</ArticleId><ArticleId IdType="pmc">PMC8603395</ArticleId><ArticleId IdType="pubmed">33027652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakoda M.E., Fazeli P.L., Ellis R.J., Jeste D.V., Grant I., Letendre S.L., Moore D.J. Higher Cystatin C Levels Are Associated with Neurocognitive Impairment in Older HIV+ Adults. J. Acquir. Immune Defic. Syndr. 2017;74:243&#x2013;249. doi: 10.1097/QAI.0000000000001235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000001235</ArticleId><ArticleId IdType="pmc">PMC5303169</ArticleId><ArticleId IdType="pubmed">27861242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Liu S., Qin Z., Cui Y., Qin Y., Bai S. Alteration of Cystatin C Levels in Cerebrospinal Fluid of Patients with Guillain-Barr&#xe9; Syndrome by a Proteomical Approach. Mol. Biol. Rep. 2009;36:677&#x2013;682. doi: 10.1007/s11033-008-9228-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-008-9228-1</ArticleId><ArticleId IdType="pubmed">18373213</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai A., Terashima M., Harada T., Shimode K., Takeuchi H., Murakawa Y., Nagasaki M., Nakano A., Kobayashi S. Cathepsin B and H Activities and Cystatin C Concentrations in Cerebrospinal Fluid from Patients with Leptomeningeal Metastasis. Clin. Chim. Acta. 2003;329:53&#x2013;60. doi: 10.1016/S0009-8981(03)00023-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-8981(03)00023-8</ArticleId><ArticleId IdType="pubmed">12589965</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy E., Jaskolski M., Grubb A. The Role of Cystatin C in Cerebral Amyloid Angiopathy and Stroke: Cell Biology and Animal Models. Brain Pathol. 2006;16:60&#x2013;70. doi: 10.1111/j.1750-3639.2006.tb00562.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2006.tb00562.x</ArticleId><ArticleId IdType="pmc">PMC8095742</ArticleId><ArticleId IdType="pubmed">16612983</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Huang W., Wei J., Yin Z., Liu H. Increased Serum Cystatin C Levels Were Associated with Depressive Symptoms in Patients with Type 2 Diabetes. Diabetes Metab. Syndr. Obes. 2021;14:857&#x2013;863. doi: 10.2147/DMSO.S295088.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DMSO.S295088</ArticleId><ArticleId IdType="pmc">PMC7920507</ArticleId><ArticleId IdType="pubmed">33658820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharples A.P., Al-Shanti N., Hughes D.C., Lewis M.P., Stewart C.E. The Role of Insulin-like-Growth Factor Binding Protein 2 (IGFBP2) and Phosphatase and Tensin Homologue (PTEN) in the Regulation of Myoblast Differentiation and Hypertrophy. Growth Horm. IGF Res. 2013;23:53&#x2013;61. doi: 10.1016/j.ghir.2013.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ghir.2013.03.004</ArticleId><ArticleId IdType="pubmed">23583027</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S. IGFBP-2 Signaling in the Brain: From Brain Development to Higher Order Brain Functions. Front. Endocrinol. 2019;10:822. doi: 10.3389/fendo.2019.00822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00822</ArticleId><ArticleId IdType="pmc">PMC6883226</ArticleId><ArticleId IdType="pubmed">31824433</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen F., Song C., Liu Y., Zhang J., Wei Song S. IGFBP2 Promotes Neural Stem Cell Maintenance and Proliferation Differentially Associated with Glioblastoma Subtypes. Brain Res. 2019;1704:174&#x2013;186. doi: 10.1016/j.brainres.2018.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.10.018</ArticleId><ArticleId IdType="pubmed">30347220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Zhang X., Song Q., Liu L., Forbes E., Tian W., Zhang Z., Kang Y., Wang H., Fleming J.B., et al. IGFBP2 Promotes Tumor Progression by Inducing Alternative Polarization of Macrophages in Pancreatic Ductal Adenocarcinoma through the STAT3 Pathway. Cancer Lett. 2021;500:132&#x2013;146. doi: 10.1016/j.canlet.2020.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.12.008</ArticleId><ArticleId IdType="pmc">PMC7923838</ArticleId><ArticleId IdType="pubmed">33309859</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Yu D.-Y., Yang Z.-F., Liu D.-Y., Cao H.-Q., Liao X.-W. IGFBP2 Upregulates ZEB1 Expression and Promotes Hepatocellular Carcinoma Progression through NF-&#x3ba;B Signaling Pathway. Dig. Liver Dis. 2020;52:573&#x2013;581. doi: 10.1016/j.dld.2019.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2019.10.008</ArticleId><ArticleId IdType="pubmed">31818638</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler N., Mayer J., Saenger S., Gimsa U., Walz C., Brenmoehl J., Ohde D., Wirthgen E., Tuchscherer A., Russo V.C., et al. Phenotype Analysis of Male Transgenic Mice Overexpressing Mutant IGFBP-2 Lacking the Cardin&#x2013;Weintraub Sequence Motif: Reduced Expression of Synaptic Markers and Myelin Basic Protein in the Brain and a Lower Degree of Anxiety-like Behaviour. Growth Horm. IGF Res. 2017;33:1&#x2013;8. doi: 10.1016/j.ghir.2016.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ghir.2016.11.003</ArticleId><ArticleId IdType="pubmed">27919008</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgdorf J., Colechio E.M., Ghoreishi-Haack N., Gross A.L., Rex C.S., Zhang X., Stanton P.K., Kroes R.A., Moskal J.R. IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity. Int. J. Neuropsychopharmacol. 2017;20:476&#x2013;484. doi: 10.1093/ijnp/pyx007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyx007</ArticleId><ArticleId IdType="pmc">PMC5458343</ArticleId><ArticleId IdType="pubmed">28158790</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauzier C., Lamarche B., Tremblay A.J., Couture P., Picard F. Associations between Insulin-like Growth Factor Binding Protein-2 and Lipoprotein Kinetics in Men. J. Lipid Res. 2022;63:100269. doi: 10.1016/j.jlr.2022.100269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jlr.2022.100269</ArticleId><ArticleId IdType="pmc">PMC9587400</ArticleId><ArticleId IdType="pubmed">36030928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Lev&#xed; A.M., Bernabeu I., Sampedro-N&#xfa;&#xf1;ez M., Marazuela M. Genetic Predictors of Response to Different Medical Therapies in Acromegaly. Prog. Mol. Biol. Transl. Sci. 2016;138:85&#x2013;114. doi: 10.1016/bs.pmbts.2015.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2015.10.016</ArticleId><ArticleId IdType="pubmed">26940388</ArticleId></ArticleIdList></Reference><Reference><Citation>Naspi A., Panasiti V., Abbate F., Roberti V., Devirgiliis V., Curzio M., Borghi M., Lozupone F., Carotti S., Morini S., et al. Insulin-Like-Growth-Factor-Binding-Protein-3 (IGFBP-3) Contrasts Melanoma Progression In Vitro and In Vivo. PLoS ONE. 2014;9:e98641. doi: 10.1371/journal.pone.0098641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098641</ArticleId><ArticleId IdType="pmc">PMC4048209</ArticleId><ArticleId IdType="pubmed">24905466</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann G. Encyclopedia of Endocrine Diseases. Elsevier; Amsterdam, The Netherlands: 2004. Growth Hormone (GH) pp. 383&#x2013;389.</Citation></Reference><Reference><Citation>Jones J.I., Clemmons D.R. Insulin-like Growth Factors and Their Binding Proteins: Biological Actions. Endocr. Rev. 1995;16:3&#x2013;34. doi: 10.1210/edrv-16-1-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/edrv-16-1-3</ArticleId><ArticleId IdType="pubmed">7758431</ArticleId></ArticleIdList></Reference><Reference><Citation>Firth S.M., Baxter R.C. Cellular Actions of the Insulin-Like Growth Factor Binding Proteins. Endocr. Rev. 2002;23:824&#x2013;854. doi: 10.1210/er.2001-0033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2001-0033</ArticleId><ArticleId IdType="pubmed">12466191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishijima T., Piriz J., Duflot S., Fernandez A.M., Gaitan G., Gomez-Pinedo U., Verdugo J.M.G., Leroy F., Soya H., Nu&#xf1;ez A., et al. Neuronal Activity Drives Localized Blood-Brain-Barrier Transport of Serum Insulin-like Growth Factor-I into the CNS. Neuron. 2010;67:834&#x2013;846. doi: 10.1016/j.neuron.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.007</ArticleId><ArticleId IdType="pubmed">20826314</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H.L., Oh Y., Gargosky S.E., Lehrnbecher T., Hintz R.L., Rosenfeld R.G. Concentrations of Insulin-like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3), IGF, and IGFBP-3 Protease Activity in Cerebrospinal Fluid of Children with Leukemia, Central Nervous System Tumor, or Meningitis. J. Clin. Endocrinol. Metab. 1993;77:1113&#x2013;1119. doi: 10.1210/jcem.77.5.7521338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.77.5.7521338</ArticleId><ArticleId IdType="pubmed">7521338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu P., Thinschmidt J.S., Caballero S., Adamson S., Cole L., Chan-Ling T., Grant M.B. Loss of Survival Factors and Activation of Inflammatory Cascades in Brain Sympathetic Centers in Type 1 Diabetic Mice. Am. J. Physiol.-Endocrinol. Metab. 2015;308:E688&#x2013;E698. doi: 10.1152/ajpendo.00504.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00504.2014</ArticleId><ArticleId IdType="pmc">PMC4398829</ArticleId><ArticleId IdType="pubmed">25714673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Huang M., Jiao J., Wu Y., Ouyang T., Huang J., Liu S., Li C. Relationship between Concentrations of IGF-1 and IGFBP-3 and Preoperative Depression Risk, and Effect of Psychological Intervention on Outcomes of High-Grade Glioma Patients with Preoperative Depression in a 2-Year Prospective Study. Med. Oncol. 2014;31:921. doi: 10.1007/s12032-014-0921-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-014-0921-8</ArticleId><ArticleId IdType="pubmed">24668415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H., Wu T. Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases. Front. Endocrinol. 2018;9:499. doi: 10.3389/fendo.2018.00499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00499</ArticleId><ArticleId IdType="pmc">PMC6125368</ArticleId><ArticleId IdType="pubmed">30214426</ArticleId></ArticleIdList></Reference><Reference><Citation>Miehle K., Ebert T., Kralisch S., Hoffmann A., Kratzsch J., Schl&#xf6;gl H., Stumvoll M., Fasshauer M. Circulating Serum Chemerin Levels Are Elevated in Lipodystrophy. Clin. Endocrinol. 2016;84:932&#x2013;938. doi: 10.1111/cen.12976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.12976</ArticleId><ArticleId IdType="pubmed">26572532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst M.C., Sinal C.J. Chemerin: At the Crossroads of Inflammation and Obesity. Trends Endocrinol. Metab. 2010;21:660&#x2013;667. doi: 10.1016/j.tem.2010.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2010.08.001</ArticleId><ArticleId IdType="pubmed">20817486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sell H., Laurencikiene J., Taube A., Eckardt K., Cramer A., Horrighs A., Arner P., Eckel J. Chemerin Is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle Cells. Diabetes. 2009;58:2731&#x2013;2740. doi: 10.2337/db09-0277.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db09-0277</ArticleId><ArticleId IdType="pmc">PMC2780878</ArticleId><ArticleId IdType="pubmed">19720798</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X.-Y., Zabel B.A., Myles T., Allen S.J., Handel T.M., Lee P.P., Butcher E.C., Leung L.L. Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-Activable Fibrinolysis Inhibitor), and Platelets. J. Biol. Chem. 2009;284:751&#x2013;758. doi: 10.1074/jbc.M805000200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805000200</ArticleId><ArticleId IdType="pmc">PMC2613638</ArticleId><ArticleId IdType="pubmed">19010784</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A., Matsumoto K., Hori K., Kameshima S., Yamaguchi N., Okada S., Okada M., Yamawaki H. Acute Intracerebroventricular Injection of Chemerin-9 Increases Systemic Blood Pressure through Activating Sympathetic Nerves via CMKLR1 in Brain. Pfl&#xfc;g. Arch. Eur. J. Physiol. 2020;472:673&#x2013;681. doi: 10.1007/s00424-020-02391-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-020-02391-4</ArticleId><ArticleId IdType="pubmed">32462328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T.H., Cheng K.K., Hoo R.L., Siu P.M., Yau S. The Novel Perspectives of Adipokines on Brain Health. Int. J. Mol. Sci. 2019;20:5638. doi: 10.3390/ijms20225638.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20225638</ArticleId><ArticleId IdType="pmc">PMC6887733</ArticleId><ArticleId IdType="pubmed">31718027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Yamaguchi Y., Sharif S., Du X.-Y., Song J.J., Lee D.M., Recht L.D., Robinson W.H., Morser J., Leung L.L.K. Chemerin158K Protein Is the Dominant Chemerin Isoform in Synovial and Cerebrospinal Fluids but Not in Plasma. J. Biol. Chem. 2011;286:39520&#x2013;39527. doi: 10.1074/jbc.M111.258954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.258954</ArticleId><ArticleId IdType="pmc">PMC3234775</ArticleId><ArticleId IdType="pubmed">21930706</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Han L., Sun D., Chen Y., Wu Q., Zhang L., Zhou M., Chen D. Chemerin-Induced Macrophages Pyroptosis in Fetal Brain Tissue Leads to Cognitive Disorder in Offspring of Diabetic Dams. J. Neuroinflammation. 2019;16:226. doi: 10.1186/s12974-019-1573-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1573-6</ArticleId><ArticleId IdType="pmc">PMC6858779</ArticleId><ArticleId IdType="pubmed">31733653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Gafa V., Serafini B., Giacomini E., Visconti A., Remoli M.E., Severa M., Parmentier M., Ristori G., Salvetti M., et al. Plasmacytoid Dendritic Cells in Multiple Sclerosis: Intracerebral Recruitment and Impaired Maturation in Response to Interferon-&#x3b2;. J. Neuropathol. Exp. Neurol. 2008;67:388&#x2013;401. doi: 10.1097/NEN.0b013e31816fc975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31816fc975</ArticleId><ArticleId IdType="pubmed">18431257</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham K.L., Zabel B.A., Loghavi S., Zuniga L.A., Ho P.P., Sobel R.A., Butcher E.C. Chemokine-Like Receptor-1 Expression by Central Nervous System-Infiltrating Leukocytes and Involvement in a Model of Autoimmune Demyelinating Disease. J. Immunol. 2009;183:6717&#x2013;6723. doi: 10.4049/jimmunol.0803435.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803435</ArticleId><ArticleId IdType="pmc">PMC2904075</ArticleId><ArticleId IdType="pubmed">19864606</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H., Otsuka T., Hitora-Imamura N., Ishimura K., Fukuda H., Fujiwara K., Shuto S., Deyama S., Minami M. Resolvin E1 Attenuates Chronic Pain-Induced Depression-Like Behavior in Mice: Possible Involvement of Chemerin Receptor ChemR23. Biol. Pharm. Bull. 2021;44:1548&#x2013;1550. doi: 10.1248/bpb.b21-00461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b21-00461</ArticleId><ArticleId IdType="pubmed">34602564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Lee J.-H., Lee S.K., Song N.-Y., Son S.H., Kim K.R., Chung W.-Y. Chemerin Treatment Inhibits the Growth and Bone Invasion of Breast Cancer Cells. Int. J. Mol. Sci. 2020;21:2871. doi: 10.3390/ijms21082871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21082871</ArticleId><ArticleId IdType="pmc">PMC7216174</ArticleId><ArticleId IdType="pubmed">32325994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Z.-N., Teng Q.-X., Tian Q., Chen W., Xie Y., Wu K., Zeng Q., Zeng L., Pan Y., Chen Z.-S., et al. Signaling Pathways and Therapeutic Interventions in Gastric Cancer. Signal Transduct. Target. Ther. 2022;7:358. doi: 10.1038/s41392-022-01190-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01190-w</ArticleId><ArticleId IdType="pmc">PMC9547882</ArticleId><ArticleId IdType="pubmed">36209270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kursawe R., Santoro N. Metabolic Syndrome in Pediatrics. Adv. Clin. Chem. 2014;65:91&#x2013;142. doi: 10.1016/b978-0-12-800141-7.00004-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-800141-7.00004-8</ArticleId><ArticleId IdType="pubmed">25233612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sell H., Divoux A., Poitou C., Basdevant A., Bouillot J.-L., Bedossa P., Tordjman J., Eckel J., Cl&#xe9;ment K. Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery. J. Clin. Endocrinol. Metab. 2010;95:2892&#x2013;2896. doi: 10.1210/jc.2009-2374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2009-2374</ArticleId><ArticleId IdType="pubmed">20375212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozaoglu K., Segal D., Shields K.A., Cummings N., Curran J.E., Comuzzie A.G., Mahaney M.C., Rainwater D.L., VandeBerg J.L., MacCluer J.W., et al. Chemerin Is Associated with Metabolic Syndrome Phenotypes in a Mexican-American Population. J. Clin. Endocrinol. Metab. 2009;94:3085&#x2013;3088. doi: 10.1210/jc.2008-1833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2008-1833</ArticleId><ArticleId IdType="pmc">PMC2730868</ArticleId><ArticleId IdType="pubmed">19470637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Q., Wang H., Zeng Y., Fang X., Wang M., Li D., Huang W., Xu Y. Circulating Chemerin Levels in Metabolic-Associated Fatty Liver Disease: A Systematic Review and Meta-Analysis. Lipids Health Dis. 2022;21:27. doi: 10.1186/s12944-022-01637-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-022-01637-7</ArticleId><ArticleId IdType="pmc">PMC8889738</ArticleId><ArticleId IdType="pubmed">35236351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloemer J., Pinky P.D., Govindarajulu M., Hong H., Judd R., Amin R.H., Moore T., Dhanasekaran M., Reed M.N., Suppiramaniam V. Role of Adiponectin in Central Nervous System Disorders. Neural Plast. 2018;2018:4593530. doi: 10.1155/2018/4593530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4593530</ArticleId><ArticleId IdType="pmc">PMC6087588</ArticleId><ArticleId IdType="pubmed">30150999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishida K., Funahashi T., Shimomura I. Adiponectin as a Routine Clinical Biomarker. Best Pract. Res. Clin. Endocrinol. Metab. 2014;28:119&#x2013;130. doi: 10.1016/j.beem.2013.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2013.08.006</ArticleId><ArticleId IdType="pubmed">24417951</ArticleId></ArticleIdList></Reference><Reference><Citation>Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., Hara K., Hada Y., Vasseur F., Froguel P., et al. Impaired Multimerization of Human Adiponectin Mutants Associated with Diabetes. Molecular Structure and Multimer Formation of Adiponectin. J. Biol. Chem. 2003;278:40352&#x2013;40363. doi: 10.1074/jbc.M300365200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300365200</ArticleId><ArticleId IdType="pubmed">12878598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon M.J., Lee G.Y., Chung J.-J., Ahn Y.H., Hong S.H., Kim J.B. Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, P38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor Alpha. Diabetes. 2006;55:2562&#x2013;2570. doi: 10.2337/db05-1322.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db05-1322</ArticleId><ArticleId IdType="pubmed">16936205</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;n M., Kovani&#x10d;ov&#xe1; Z., Ko&#x161;utzk&#xe1; Z., Nemec M., Tomkov&#xe1; M., Jackov&#xe1; L., M&#xe1;derov&#xe1; D., Slobodov&#xe1; L., Valkovi&#x10d; P., Ukropec J., et al. Effects of Running on Adiponectin, Insulin and Cytokines in Cerebrospinal Fluid in Healthy Young Individuals. Sci. Rep. 2019;9:1959. doi: 10.1038/s41598-018-38201-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-38201-2</ArticleId><ArticleId IdType="pmc">PMC6374465</ArticleId><ArticleId IdType="pubmed">30760755</ArticleId></ArticleIdList></Reference><Reference><Citation>Diep Nguyen T. Adiponectin: Role in Physiology and Pathophysiology. Int. J. Prev. Med. 2020;11:136. doi: 10.4103/ijpvm.IJPVM_193_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijpvm.IJPVM_193_20</ArticleId><ArticleId IdType="pmc">PMC7554603</ArticleId><ArticleId IdType="pubmed">33088464</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheid M.P., Sweeney G. The Role of Adiponectin Signaling in Metabolic Syndrome and Cancer. Rev. Endocr. Metab. Disord. 2014;15:157&#x2013;167. doi: 10.1007/s11154-013-9265-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-013-9265-5</ArticleId><ArticleId IdType="pubmed">24019064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnsburger M., Djuric N., Mulder I.A., de Vries H.E. Adipokines as Immune Cell Modulators in Multiple Sclerosis. Int. J. Mol. Sci. 2021;22:10845. doi: 10.3390/ijms221910845.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910845</ArticleId><ArticleId IdType="pmc">PMC8509121</ArticleId><ArticleId IdType="pubmed">34639186</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyirenda M.H., Fadda G., Healy L.M., Mexhitaj I., Poliquin-Lasnier L., Hanwell H., Saveriano A.W., Rozenberg A., Li R., Moore C.S., et al. Pro-Inflammatory Adiponectin in Pediatric-Onset Multiple Sclerosis. Mult. Scler. J. 2021;27:1948&#x2013;1959. doi: 10.1177/1352458521989090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458521989090</ArticleId><ArticleId IdType="pubmed">33522403</ArticleId></ArticleIdList></Reference><Reference><Citation>Thundyil J., Pavlovski D., Sobey C.G., Arumugam T.V. Adiponectin Receptor Signalling in the Brain. Br. J. Pharmacol. 2012;165:313&#x2013;327. doi: 10.1111/j.1476-5381.2011.01560.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01560.x</ArticleId><ArticleId IdType="pmc">PMC3268187</ArticleId><ArticleId IdType="pubmed">21718299</ArticleId></ArticleIdList></Reference><Reference><Citation>Waragai M., Ho G., Takamatsu Y., Sekiyama K., Sugama S., Takenouchi T., Masliah E., Hashimoto M. Importance of Adiponectin Activity in the Pathogenesis of Alzheimer&#x2019;s Disease. Ann. Clin. Transl. Neurol. 2017;4:591&#x2013;600. doi: 10.1002/acn3.436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.436</ArticleId><ArticleId IdType="pmc">PMC5553221</ArticleId><ArticleId IdType="pubmed">28812049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng R.C.-L., Chan K.-H. Potential Neuroprotective Effects of Adiponectin in Alzheimer&#x2019;s Disease. Int. J. Mol. Sci. 2017;18:592. doi: 10.3390/ijms18030592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030592</ArticleId><ArticleId IdType="pmc">PMC5372608</ArticleId><ArticleId IdType="pubmed">28282917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.W., Abid N.B., Jo M.H., Jo M.G., Yoon G.H., Kim M.O. Suppression of Adiponectin Receptor 1 Promotes Memory Dysfunction and Alzheimer&#x2019;s Disease-like Pathologies. Sci. Rep. 2017;7:12435. doi: 10.1038/s41598-017-12632-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-12632-9</ArticleId><ArticleId IdType="pmc">PMC5622055</ArticleId><ArticleId IdType="pubmed">28963462</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J., Shen L.-H., Tang Y.-H., Wang Y.-T., Tao M.-X., Jin K.-L., Zhao Y.-J., Yang G.-Y. Overexpression of Adiponectin Improves Neurobehavioral Outcomes after Focal Cerebral Ischemia in Aged Mice. CNS Neurosci. Ther. 2013;19:969&#x2013;977. doi: 10.1111/cns.12198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12198</ArticleId><ArticleId IdType="pmc">PMC6493541</ArticleId><ArticleId IdType="pubmed">24164711</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J., Kang S.M., Kim E., Kim C.-H., Song H.-T., Lee J.E. Adiponectin Receptor-Mediated Signaling Ameliorates Cerebral Cell Damage and Regulates the Neurogenesis of Neural Stem Cells at High Glucose Concentrations: An in Vivo and in Vitro Study. Cell Death Dis. 2015;6:e1844. doi: 10.1038/cddis.2015.220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.220</ArticleId><ArticleId IdType="pmc">PMC4558511</ArticleId><ArticleId IdType="pubmed">26247729</ArticleId></ArticleIdList></Reference><Reference><Citation>Signoriello E., Mallardo M., Nigro E., Polito R., Casertano S., Di Pietro A., Coletta M., Monaco M.L., Rossi F., Lus G., et al. Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease. Mol. Neurobiol. 2021;58:2663&#x2013;2670. doi: 10.1007/s12035-021-02287-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02287-z</ArticleId><ArticleId IdType="pmc">PMC8128828</ArticleId><ArticleId IdType="pubmed">33486671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Guo Y., Ge Z., Zhang Z., Da Y., Li W., Zhang Z., Xue Z., Li Y., Ren Y., et al. Adiponectin Suppresses T Helper 17 Cell Differentiation and Limits Autoimmune CNS Inflammation via the SIRT1/PPAR&#x3b3;/ROR&#x3b3;t Pathway. Mol. Neurobiol. 2017;54:4908&#x2013;4920. doi: 10.1007/s12035-016-0036-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0036-7</ArticleId><ArticleId IdType="pubmed">27514756</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer C., Hampartzoumian T., Lloyd A., Zekry A. A Novel Role for Adiponectin in Regulating the Immune Responses in Chronic Hepatitis C Virus Infection. Hepatology. 2008;48:374&#x2013;384. doi: 10.1002/hep.22387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.22387</ArticleId><ArticleId IdType="pubmed">18666256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant&#xf3; E., Tintor&#xe9; M., Villar L.M., Costa C., Nurtdinov R., &#xc1;lvarez-Cerme&#xf1;o J.C., Arrambide G., Reverter F., Deisenhammer F., Hegen H., et al. Chitinase 3-like 1: Prognostic Biomarker in Clinically Isolated Syndromes. Brain. 2015;138:918&#x2013;931. doi: 10.1093/brain/awv017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv017</ArticleId><ArticleId IdType="pubmed">25688078</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D., Bissel S.J., Wang G., Fish K.N., Nicholl G.C.B., Darko S.W., Medina-Flores R., Murphey-Corb M., Rajakumar P.A., Nyaundi J., et al. YKL-40, a Marker of Simian Immunodeficiency Virus Encephalitis, Modulates the Biological Activity of Basic Fibroblast Growth Factor. Am. J. Pathol. 2008;173:130&#x2013;143. doi: 10.2353/ajpath.2008.080045.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080045</ArticleId><ArticleId IdType="pmc">PMC2438291</ArticleId><ArticleId IdType="pubmed">18556781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinteac R., Montalban X., Comabella M. Chitinases and Chitinase-like Proteins as Biomarkers in Neurologic Disorders. Neurol. Neuroimmunol. Neuroinflammation. 2021;8:e921. doi: 10.1212/NXI.0000000000000921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000921</ArticleId><ArticleId IdType="pmc">PMC7803328</ArticleId><ArticleId IdType="pubmed">33293459</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathcke C.N., Vestergaard H. YKL-40, a New Inflammatory Marker with Relation to Insulin Resistance and with a Role in Endothelial Dysfunction and Atherosclerosis. Inflamm. Res. 2006;55:221&#x2013;227. doi: 10.1007/s00011-006-0076-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-006-0076-y</ArticleId><ArticleId IdType="pubmed">16955240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kzhyshkowska J., Gratchev A., Goerdt S. Human Chitinases and Chitinase-like Proteins as Indicators for Inflammation and Cancer. Biomark. Insights. 2007;2:128&#x2013;146. doi: 10.1177/117727190700200023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/117727190700200023</ArticleId><ArticleId IdType="pmc">PMC2717817</ArticleId><ArticleId IdType="pubmed">19662198</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly K., Lehoux M., O&#x2019;Rourke R., Assetta B., Erdemir G.A., Elias J.A., Lee C.G., Huang Y.-W.A. Potential Role of Chitinase-3-like Protein 1 (CHI3L1/YKL-40) in Neurodegeneration and Alzheimer&#x2019;s Disease. Alzheimers Dement. J. Alzheimers Assoc. 2023;19:9&#x2013;24. doi: 10.1002/alz.12612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12612</ArticleId><ArticleId IdType="pmc">PMC9437141</ArticleId><ArticleId IdType="pubmed">35234337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Su Z., Li Y., Zhang X., You Q. Chitinase-3 like-Protein-1 Function and Its Role in Diseases. Signal Transduct. Target. Ther. 2020;5:201. doi: 10.1038/s41392-020-00303-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00303-7</ArticleId><ArticleId IdType="pmc">PMC7490424</ArticleId><ArticleId IdType="pubmed">32929074</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabias C.S., Gomez P.A., Panero I., Eiriz C., Casta&#xf1;o-Le&#xf3;n A.M., Egea J., Lagares A., Paredes I., Fern&#xe1;ndez Al&#xe9;n J.A., Moreno-G&#xf3;mez L.M., et al. Chitinase-3-Like Protein 1, Serum Amyloid A1, C-Reactive Protein, and Procalcitonin Are Promising Biomarkers for Intracranial Severity Assessment of Traumatic Brain Injury: Relationship with Glasgow Coma Scale and Computed Tomography Volumetry. World Neurosurg. 2020;134:e120&#x2013;e143. doi: 10.1016/j.wneu.2019.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2019.09.143</ArticleId><ArticleId IdType="pubmed">31606503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin B., Inanli I., Caliskan A.M., Uysal S. Chitinase-3-like Protein 1 Levels in Bipolar Disorder. Saudi Med. J. 2019;40:26&#x2013;32. doi: 10.15537/smj.2019.1.23396.</Citation><ArticleIdList><ArticleId IdType="doi">10.15537/smj.2019.1.23396</ArticleId><ArticleId IdType="pmc">PMC6452616</ArticleId><ArticleId IdType="pubmed">30617377</ArticleId></ArticleIdList></Reference><Reference><Citation>Czupryna P., Kulczy&#x144;ka-Przybik A., Mroczko B., Wondim M.A., Grygorczuk S., Borawski K., Pancewicz S., Moniuszko-Malinowska A. Assessment of the YKL-40 Concentration in Patients with Tick-Borne Encephalitis. Ticks Tick-Borne Dis. 2022;13:101895. doi: 10.1016/j.ttbdis.2022.101895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ttbdis.2022.101895</ArticleId><ArticleId IdType="pubmed">35042079</ArticleId></ArticleIdList></Reference><Reference><Citation>Constant O., Barthelemy J., Nagy A., Salinas S., Simonin Y. West Nile Virus Neuroinfection in Humans: Peripheral Biomarkers of Neuroinflammation and Neuronal Damage. Viruses. 2022;14:756. doi: 10.3390/v14040756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14040756</ArticleId><ArticleId IdType="pmc">PMC9027124</ArticleId><ArticleId IdType="pubmed">35458486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissel S.J., Kofler J., Nyaundi J., Murphey-Corb M., Wisniewski S.R., Wiley C.A. Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis: CSF Biomarkers of SIV Encephalitis. J. Neuroimmune Pharmacol. 2016;11:332&#x2013;347. doi: 10.1007/s11481-016-9666-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-016-9666-9</ArticleId><ArticleId IdType="pmc">PMC4871628</ArticleId><ArticleId IdType="pubmed">27059917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin B., Wu S., Liu Y., Liu L., Mushtaq S. Chitinase-3-like Protein 1 as a Predictor for the Progression or Regression of Liver Fibrosis. Hepatoma Res. 2018;4:48. doi: 10.20517/2394-5079.2018.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/2394-5079.2018.19</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian J., Chen Y., Liberti R., Fu W., Hu W., Saunders-Pullman R., Pastores G.M., Chen Y., Sun Y., Grabowski G.A., et al. Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease. EBioMedicine. 2018;28:251&#x2013;260. doi: 10.1016/j.ebiom.2018.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.01.022</ArticleId><ArticleId IdType="pmc">PMC5835567</ArticleId><ArticleId IdType="pubmed">29396296</ArticleId></ArticleIdList></Reference><Reference><Citation>Khattab F.M., Said N.M. Chitinase-3-like Protein 1 (YKL-40): Novel Biomarker of Lichen Planus. Int. J. Dermatol. 2019;58:993&#x2013;996. doi: 10.1111/ijd.14551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijd.14551</ArticleId><ArticleId IdType="pubmed">31231798</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon J., Matusiak &#x141;., Nowicka-Suszko D., Szepietowski J. Chitinase-3-like Protein 1 (YKL-40) Is a Biomarker of Severity of Joint Involvement in Psoriatic Arthritis. Adv. Dermatol. Allergol. 2018;35:485&#x2013;489. doi: 10.5114/ada.2018.77239.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ada.2018.77239</ArticleId><ArticleId IdType="pmc">PMC6232549</ArticleId><ArticleId IdType="pubmed">30429706</ArticleId></ArticleIdList></Reference><Reference><Citation>Areshkov P.A., Kavsan V.M. Chitinase 3-like Protein 2 (CHI3L2, YKL-39) Activates Phosphorylation of Extracellular Signal-Regulated Kinases ERK1/ERK2 in Human Embryonic Kidney (HEK293) and Human Glioblastoma (U87 MG) Cells. Cytol. Genet. 2010;44:1&#x2013;6. doi: 10.3103/S0095452710010019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3103/S0095452710010019</ArticleId><ArticleId IdType="pubmed">20201406</ArticleId></ArticleIdList></Reference><Reference><Citation>Smitka K., Mare&#x161;ov&#xe1; D. Adipose Tissue as an Endocrine Organ: An Update on Pro-Inflammatory and Anti-Inflammatory Microenvironment. Prague Med. Rep. 2015;116:87&#x2013;111. doi: 10.14712/23362936.2015.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.14712/23362936.2015.49</ArticleId><ArticleId IdType="pubmed">26093665</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuruha J.-I., Masuko-Hongo K., Kato T., Sakata M., Nakamura H., Sekine T., Takigawa M., Nishioka K. Autoimmunity against YKL-39, a Human Cartilage Derived Protein, in Patients with Osteoarthritis. J. Rheumatol. 2002;29:1459&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136906</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa M.D., Tibullo D., Malaguarnera M., Tuttobene M., Malaguarnera L. Comparison of YKL-39 and CHIT-1 Expression during Macrophages Differentiation and Polarization. Mod. Res. Inflamm. 2013;2:82&#x2013;89. doi: 10.4236/mri.2013.24011.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/mri.2013.24011</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T., Li Y., Su Y., Zuo P., Gao Z., Ke K. Serum Omentin-1 and Risk of One-Year Mortality in Patients with Ischemic Stroke. Clin. Chim. Acta. 2020;505:167&#x2013;171. doi: 10.1016/j.cca.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.03.007</ArticleId><ArticleId IdType="pubmed">32145276</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura S., Asano Y., Saigusa R., Yamashita T., Taniguchi T., Takahashi T., Ichimura Y., Toyama T., Tamaki Z., Tada Y., et al. Serum Omentin Levels: A Possible Contribution to Vascular Involvement in Patients with Systemic Sclerosis. J. Dermatol. 2015;42:461&#x2013;466. doi: 10.1111/1346-8138.12824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.12824</ArticleId><ArticleId IdType="pubmed">25766303</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue J., Chen J., Wu Q., Liu X., Li M., Li Z., Gao Y. Serum Levels of Omentin-1 Association with Early Diagnosis, Lesion Volume and Severity of Acute Ischemic Stroke. Cytokine. 2018;111:518&#x2013;522. doi: 10.1016/j.cyto.2018.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2018.05.026</ArticleId><ArticleId IdType="pubmed">29880272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocijancic M., Vujicic B., Racki S., Cubranic Z., Zaputovic L., Dvornik S. Serum Omentin-1 Levels as a Possible Risk Factor of Mortality in Patients with Diabetes on Haemodialysis. Diabetes Res. Clin. Pract. 2015;110:44&#x2013;50. doi: 10.1016/j.diabres.2015.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2015.06.008</ArticleId><ArticleId IdType="pubmed">26293449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L.-R., Du Y.-J., Chen L., Liu Z.-G., Jia X.-Y., Pan Y.-H., Liu J.-F., Liu B. Omentin-1 Promotes the Growth of Neural Stem Cells via Activation of Akt Signaling. Mol. Med. Rep. 2015;11:1859&#x2013;1864. doi: 10.3892/mmr.2014.2937.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2937</ArticleId><ArticleId IdType="pubmed">25394413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilinca M.C., Barabas-Hajdu E.C., Ferencz G.T., Nemes-Nagy E. Involvement of Inflammatory Cytokines in Obesity and Its Complications. Rev. Romana Med. Lab. 2018;26:359&#x2013;371. doi: 10.2478/rrlm-2018-0019.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rrlm-2018-0019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhang B., Hao C., Huang X., Li X., Huang Y., Luo Z. Omentin-A Novel Adipokine in Respiratory Diseases. Int. J. Mol. Sci. 2017;19:73. doi: 10.3390/ijms19010073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010073</ArticleId><ArticleId IdType="pmc">PMC5796023</ArticleId><ArticleId IdType="pubmed">29283409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama K., Okada M., Yamawaki H. A Novel Adipocytokine, Omentin, Inhibits Platelet-Derived Growth Factor-BB-Induced Vascular Smooth Muscle Cell Migration through Antioxidative Mechanism. Am. J. Physiol. Heart Circ. Physiol. 2014;306:H1714&#x2013;H1719. doi: 10.1152/ajpheart.00048.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00048.2014</ArticleId><ArticleId IdType="pubmed">24727494</ArticleId></ArticleIdList></Reference><Reference><Citation>Opatrilova R., Caprnda M., Kubatka P., Valentova V., Uramova S., Nosal V., Gaspar L., Zachar L., Mozos I., Petrovic D., et al. Adipokines in Neurovascular Diseases. Biomed. Pharmacother. 2018;98:424&#x2013;432. doi: 10.1016/j.biopha.2017.12.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.12.074</ArticleId><ArticleId IdType="pubmed">29278852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L., Zhang L., Liang Z., Zhong S., Liu X., Liu Z., Poon W.S., Song Y., Chen B., Wang R. Role of the Omentin-1 in Susceptibility to Anxiety and Depression Like Behaviors. Moll. Cell. Endocrinol. 2023;574:111990. doi: 10.1016/j.mce.2023.111990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2023.111990</ArticleId><ArticleId IdType="pubmed">37321286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Gao Y. Clinical Relevance of Serum Omentin-1 Levels as a Biomarker of Prognosis in Patients with Acute Cerebral Infarction. Brain Behav. 2020;10:e01678. doi: 10.1002/brb3.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1678</ArticleId><ArticleId IdType="pmc">PMC7375127</ArticleId><ArticleId IdType="pubmed">32478488</ArticleId></ArticleIdList></Reference><Reference><Citation>Briana D.D., Boutsikou M., Baka S., Gourgiotis D., Marmarinos A., Liosi S., Hassiakos D., Malamitsi-Puchner A. Omentin-1 and Vaspin Are Present in the Fetus and Neonate, and Perinatal Concentrations Are Similar in Normal and Growth-Restricted Pregnancies. Metabolism. 2011;60:486&#x2013;490. doi: 10.1016/j.metabol.2010.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2010.04.014</ArticleId><ArticleId IdType="pubmed">20488498</ArticleId></ArticleIdList></Reference><Reference><Citation>Azamar-Llamas D., Hern&#xe1;ndez-Molina G., Ramos-&#xc1;valos B., Furuzawa-Carballeda J. Adipokine Contribution to the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2017;2017:5468023. doi: 10.1155/2017/5468023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5468023</ArticleId><ArticleId IdType="pmc">PMC5401756</ArticleId><ArticleId IdType="pubmed">28490838</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A., Magnuson A., Fouts J., Foster M.T. Adipose Tissue: An Endocrine Organ Playing a Role in Metabolic Regulation. Horm. Mol. Biol. Clin. Investig. 2016;26:25&#x2013;42. doi: 10.1515/hmbci-2015-0073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hmbci-2015-0073</ArticleId><ArticleId IdType="pubmed">26910750</ArticleId></ArticleIdList></Reference><Reference><Citation>Musovic S., Shrestha M.M., Komai A.M., Olofsson C.S. Resistin Is Co-Secreted with Adiponectin in White Mouse Adipocytes. Biochem. Biophys. Res. Commun. 2021;534:707&#x2013;713. doi: 10.1016/j.bbrc.2020.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.11.013</ArticleId><ArticleId IdType="pubmed">33261886</ArticleId></ArticleIdList></Reference><Reference><Citation>Korzh O., Krasnokutskiy S., Lavrova Y. Relationship between Elevated Levels of Resistin and Prothrombotic State in Type 2 Diabetes Mellitus. Metabolism. 2021;116:154494. doi: 10.1016/j.metabol.2020.154494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154494</ArticleId></ArticleIdList></Reference><Reference><Citation>Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The Hormone Resistin Links Obesity to Diabetes. Nature. 2001;409:307&#x2013;312. doi: 10.1038/35053000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35053000</ArticleId><ArticleId IdType="pubmed">11201732</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W., Kastin A.J. Adipokines and the blood-brain barrier. Peptides. 2007;28:1317. doi: 10.1016/j.peptides.2007.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2007.04.023</ArticleId><ArticleId IdType="pmc">PMC2040301</ArticleId><ArticleId IdType="pubmed">17540480</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Kaundal R.K., Zhao B., Bouchareb R., Lebeche D. Resistin Induces Cardiac Fibroblast-Myofibroblast Differentiation through JAK/STAT3 and JNK/c-Jun Signaling. Pharmacol. Res. 2021;167:105414. doi: 10.1016/j.phrs.2020.105414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.105414</ArticleId><ArticleId IdType="pmc">PMC8085100</ArticleId><ArticleId IdType="pubmed">33524540</ArticleId></ArticleIdList></Reference><Reference><Citation>Moniuszko A., Pancewicz S., Czupryna P., Grygorczuk S., &#x15a;wierzbi&#x144;ska R., Kondrusik M., Penza P., Zajkowska J. ssICAM-1, IL-21 and IL-23 in Patients with Tick Borne Encephalitis and Neuroborreliosis. Cytokine. 2012;60:468&#x2013;472. doi: 10.1016/j.cyto.2012.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2012.05.007</ArticleId><ArticleId IdType="pmc">PMC7128343</ArticleId><ArticleId IdType="pubmed">22705151</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisternas P., Martinez M., Ahima R.S., William Wong G., Inestrosa N.C. Modulation of Glucose Metabolism in Hippocampal Neurons by Adiponectin and Resistin. Mol. Neurobiol. 2019;56:3024&#x2013;3037. doi: 10.1007/s12035-018-1271-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1271-x</ArticleId><ArticleId IdType="pmc">PMC7672532</ArticleId><ArticleId IdType="pubmed">30076527</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X.-Q., Yang S.-B., Zhu F.-L., Lv Q.-W., Zhang G.-H., Huang H.-B. Resistin Is Associated with Mortality in Patients with Traumatic Brain Injury. Crit. Care. 2010;14:R190. doi: 10.1186/cc9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9307</ArticleId><ArticleId IdType="pmc">PMC3219297</ArticleId><ArticleId IdType="pubmed">21029428</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahpolat M., Ari M., Kokacya M.H. Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia. Clin. Psychopharmacol. Neurosci. 2020;18:109&#x2013;115. doi: 10.9758/cpn.2020.18.1.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2020.18.1.109</ArticleId><ArticleId IdType="pmc">PMC7006973</ArticleId><ArticleId IdType="pubmed">31958911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Li J.-Y., He P.-P., Yu X.-H., Tang C.-K. Resistin: Potential Biomarker and Therapeutic Target in Atherosclerosis. Clin. Chim. Acta. 2021;512:84&#x2013;91. doi: 10.1016/j.cca.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.11.010</ArticleId><ArticleId IdType="pubmed">33248946</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Li S.-H., Wang C.-H., Fedak P.W.M., Li R.-K., Weisel R.D., Mickle D.A.G. Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction. Circulation. 2003;108:736&#x2013;740. doi: 10.1161/01.CIR.0000084503.91330.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000084503.91330.49</ArticleId><ArticleId IdType="pubmed">12874180</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;tsch J., Adelmann M., Englaro P., D&#xf6;tsch A., H&#xe4;nze J., Blum W.F., Kiess W., Rascher W. Relation of Leptin and Neuropeptide Y in Human Blood and Cerebrospinal Fluid. J. Neurol. Sci. 1997;151:185&#x2013;188. doi: 10.1016/S0022-510X(97)00116-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00116-0</ArticleId><ArticleId IdType="pubmed">9349674</ArticleId></ArticleIdList></Reference><Reference><Citation>Morton G.J., Cummings D.E., Baskin D.G., Barsh G.S., Schwartz M.W. Central Nervous System Control of Food Intake and Body Weight. Nature. 2006;443:289&#x2013;295. doi: 10.1038/nature05026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05026</ArticleId><ArticleId IdType="pubmed">16988703</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich M.O., Spuch C., Antequera D., Rodal I., de Y&#xe9;benes J.G., Molina J.A., Bermejo F., Carro E. Megalin Mediates the Transport of Leptin across the Blood-CSF Barrier. Neurobiol. Aging. 2008;29:902&#x2013;912. doi: 10.1016/j.neurobiolaging.2007.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.01.008</ArticleId><ArticleId IdType="pubmed">17324488</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S., Roseberry A.G., Liu H., Diano S., Shanabrough M., Cai X., Friedman J.M., Horvath T.L. Rapid Rewiring of Arcuate Nucleus Feeding Circuits by Leptin. Science. 2004;304:110&#x2013;115. doi: 10.1126/science.1089459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1089459</ArticleId><ArticleId IdType="pubmed">15064421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowley M.A., Smart J.L., Rubinstein M., Cerd&#xe1;n M.G., Diano S., Horvath T.L., Cone R.D., Low M.J. Leptin Activates Anorexigenic POMC Neurons through a Neural Network in the Arcuate Nucleus. Nature. 2001;411:480&#x2013;484. doi: 10.1038/35078085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35078085</ArticleId><ArticleId IdType="pubmed">11373681</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Spiezio A., Sandin E.S., Dore R., M&#xfc;ller-Fielitz H., Storck S.E., Bernau M., Mier W., Oster H., J&#xf6;hren O., Pietrzik C.U., et al. The LepR-Mediated Leptin Transport across Brain Barriers Controls Food Reward. Mol. Metab. 2018;8:13&#x2013;22. doi: 10.1016/j.molmet.2017.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2017.12.001</ArticleId><ArticleId IdType="pmc">PMC5985039</ArticleId><ArticleId IdType="pubmed">29254602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P.K., Hsuchou H., Ouyang S., Kastin A.J., Wu X., Pan W. Loss of Astrocytic Leptin Signaling Worsens Experimental Autoimmune Encephalomyelitis. Brain. Behav. Immun. 2013;34:98&#x2013;107. doi: 10.1016/j.bbi.2013.07.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.07.176</ArticleId><ArticleId IdType="pmc">PMC3818286</ArticleId><ArticleId IdType="pubmed">23916894</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylan A., Akinci B., Toprak B., Birlik M., Arslan F.D., Ekerbicer H., Gundogdu B., Colak A., Engin B. Association of Leptin Levels and Disease Activity in Patients with Early Rheumatoid Arthritis. Arch. Med. Res. 2021;52:544&#x2013;553. doi: 10.1016/j.arcmed.2021.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.02.002</ArticleId><ArticleId IdType="pubmed">33632629</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna V., Di Giacomo A., La Cava A., Lechler R.I., Fontana S., Zappacosta S., Matarese G. Leptin Surge Precedes Onset of Autoimmune Encephalomyelitis and Correlates with Development of Pathogenic T Cell Responses. J. Clin. Invest. 2003;111:241&#x2013;250. doi: 10.1172/JCI200316721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200316721</ArticleId><ArticleId IdType="pmc">PMC151876</ArticleId><ArticleId IdType="pubmed">12531880</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Huang X., Ye X., Li X., Wei J. Roles of Leptin on the Key Effector Cells of Rheumatoid Arthritis. Immunol. Lett. 2021;233:92&#x2013;96. doi: 10.1016/j.imlet.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2021.02.008</ArticleId><ArticleId IdType="pubmed">33652029</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X., Zhang G., Cheng Y., Wang B. Leptin in Skin Disease Modulation. Clin. Chim. Acta. 2021;516:8&#x2013;14. doi: 10.1016/j.cca.2021.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.01.013</ArticleId><ArticleId IdType="pubmed">33485901</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero M., Lago R., Gomez R., Lago F., Dieguez C., G&#xf3;mez-Reino J.J., Gualillo O. Changes in Plasma Levels of Fat-Derived Hormones Adiponectin, Leptin, Resistin and Visfatin in Patients with Rheumatoid Arthritis. Ann. Rheum. Dis. 2006;65:1198&#x2013;1201. doi: 10.1136/ard.2005.046540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.046540</ArticleId><ArticleId IdType="pmc">PMC1798289</ArticleId><ArticleId IdType="pubmed">16414972</ArticleId></ArticleIdList></Reference><Reference><Citation>Corem N., Anzi S., Gelb S., Ben-Zvi A. Leptin Receptor Deficiency Induces Early, Transient and Hyperglycaemia-Independent Blood-Brain Barrier Dysfunction. Sci. Rep. 2019;9:2884. doi: 10.1038/s41598-019-39230-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39230-1</ArticleId><ArticleId IdType="pmc">PMC6393679</ArticleId><ArticleId IdType="pubmed">30814586</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Silva A.A., Hall J.E., Dai X., Wang Z., Salgado M.C., do Carmo J.M. Chronic Antidiabetic Actions of Leptin: Evidence from Parabiosis Studies for a CNS-Derived Circulating Antidiabetic Factor. Diabetes. 2021;70:2264&#x2013;2274. doi: 10.2337/db21-0126.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0126</ArticleId><ArticleId IdType="pmc">PMC8576509</ArticleId><ArticleId IdType="pubmed">34344788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra-Honigmann M.R., Nath A.K., Murakami C., Garc&#xed;a-Carde&#xf1;a G., Papapetropoulos A., Sessa W.C., Madge L.A., Schechner J.S., Schwabb M.B., Polverini P.J., et al. Biological Action of Leptin as an Angiogenic Factor. Science. 1998;281:1683&#x2013;1686. doi: 10.1126/science.281.5383.1683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5383.1683</ArticleId><ArticleId IdType="pubmed">9733517</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston A., Arnadottir S., Gudjonsson J.E., Aphale A., Sigmarsdottir A.A., Gunnarsson S.I., Steinsson J.T., Elder J.T., Valdimarsson H. Obesity in Psoriasis: Leptin and Resistin as Mediators of Cutaneous Inflammation. Br. J. Dermatol. 2008;159:342&#x2013;350. doi: 10.1111/j.1365-2133.2008.08655.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2008.08655.x</ArticleId><ArticleId IdType="pmc">PMC2757771</ArticleId><ArticleId IdType="pubmed">18547319</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A., Matarese G. The Weight of Leptin in Immunity. Nat. Rev. Immunol. 2004;4:371&#x2013;379. doi: 10.1038/nri1350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1350</ArticleId><ArticleId IdType="pubmed">15122202</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesh Y., Sarkar D. Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. Int. J. Mol. Sci. 2021;22:2163. doi: 10.3390/ijms22042163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22042163</ArticleId><ArticleId IdType="pmc">PMC7926723</ArticleId><ArticleId IdType="pubmed">33671547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Liu Q. Cholesterol Metabolism and Homeostasis in the Brain. Protein Cell. 2015;6:254&#x2013;264. doi: 10.1007/s13238-014-0131-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0131-3</ArticleId><ArticleId IdType="pmc">PMC4383754</ArticleId><ArticleId IdType="pubmed">25682154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturny M., Anguenot L., Costa-Fraga F.P., Bragina M.E., Lima A.M., da Silva R.F., Fraga-Silva R.A., Stergiopulos N. Apelin-13 Protects Corpus Cavernosum Against Fibrosis Induced by High-Fat Diet in an MMP-Dependent Mechanism. J. Sex. Med. 2021;18:875&#x2013;888. doi: 10.1016/j.jsxm.2021.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsxm.2021.02.004</ArticleId><ArticleId IdType="pubmed">33863684</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Shuai N., Wang B., Jin X., Kuang X., Tian S. Neuroprotective Gain of Apelin/APJ System. Neuropeptides. 2021;87:102131. doi: 10.1016/j.npep.2021.102131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2021.102131</ArticleId><ArticleId IdType="pubmed">33640616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Y., Wang W., Chen L., Lu W., Xu M. Serum Apelin-13 and Risk of Death Following Severe Traumatic Brain Injury. Clin. Chim. Acta. 2021;516:64&#x2013;68. doi: 10.1016/j.cca.2021.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.01.014</ArticleId><ArticleId IdType="pubmed">33508251</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Li T., Gao L., Zheng J., Yan J., Zhang J., Shao A. Apelin-13/APJ System Attenuates Early Brain Injury via Suppression of Endoplasmic Reticulum Stress-Associated TXNIP/NLRP3 Inflammasome Activation and Oxidative Stress in a AMPK-Dependent Manner after Subarachnoid Hemorrhage in Rats. J. Neuroinflamm. 2019;16:247. doi: 10.1186/s12974-019-1620-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1620-3</ArticleId><ArticleId IdType="pmc">PMC6889224</ArticleId><ArticleId IdType="pubmed">31791369</ArticleId></ArticleIdList></Reference><Reference><Citation>Vafaei-Nezhad S., Niknazar S., Norouzian M., Abdollahifar M.-A., Aliaghaei A., Abbaszadeh H.A. Therapeutics Effects of [Pyr1] Apelin-13 on Rat Contusion Model of Spinal Cord Injury: An Experimental Study. J. Chem. Neuroanat. 2021;113:101924. doi: 10.1016/j.jchemneu.2021.101924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2021.101924</ArticleId><ArticleId IdType="pubmed">33567298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai A., Kinjo T., Ishihara R., Sakai I., Ishimaru Y., Yoshioka Y., Yamamuro A., Ishige K., Ito Y., Maeda S. Apelin Deficiency Accelerates the Progression of Amyotrophic Lateral Sclerosis. PLoS ONE. 2011;6:e23968. doi: 10.1371/journal.pone.0023968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023968</ArticleId><ArticleId IdType="pmc">PMC3161091</ArticleId><ArticleId IdType="pubmed">21887354</ArticleId></ArticleIdList></Reference><Reference><Citation>Karl T., Hoffmann T., Pabst R., von H&#xf6;rsten S. Behavioral Effects of Neuropeptide Y in F344 Rat Substrains with a Reduced Dipeptidyl-Peptidase IV Activity. Pharmacol. Biochem. Behav. 2003;75:869&#x2013;879. doi: 10.1016/S0091-3057(03)00154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-3057(03)00154-0</ArticleId><ArticleId IdType="pubmed">12957230</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhold D., Biton A., Pieper S., Lendeckel U., Faust J., Neubert K., Bank U., T&#xe4;ger M., Ansorge S., Brocke S. Dipeptidyl Peptidase IV (DP IV, CD26) and Aminopeptidase N (APN, CD13) as Regulators of T Cell Function and Targets of Immunotherapy in CNS Inflammation. Int. Immunopharmacol. 2006;6:1935&#x2013;1942. doi: 10.1016/j.intimp.2006.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2006.07.023</ArticleId><ArticleId IdType="pubmed">17161346</ArticleId></ArticleIdList></Reference><Reference><Citation>Karl T., Hoffmann T., Pabst R., von H&#xf6;rsten S. Extreme Reduction of Dipeptidyl Peptidase IV Activity in F344 Rat Substrains Is Associated with Various Behavioral Differences. Physiol. Behav. 2003;80:123&#x2013;134. doi: 10.1016/S0031-9384(03)00229-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-9384(03)00229-4</ArticleId><ArticleId IdType="pubmed">14568317</ArticleId></ArticleIdList></Reference><Reference><Citation>Elabi O.F., Karampatsi D., Vercalsteren E., Lietzau G., Nystr&#xf6;m T., Klein T., Darsalia V., Patrone C., Paul G. DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes&#x2013;Induced Blood&#x2013;Brain Barrier Leakage and Normalize Capillary Pericyte Coverage. Diabetes. 2023;72:405&#x2013;414. doi: 10.2337/db22-0674.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db22-0674</ArticleId><ArticleId IdType="pmc">PMC9935496</ArticleId><ArticleId IdType="pubmed">36448982</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamali-Raeufy N., Barati H., Baluchnejadmojarad T., Roghani M., Goudarzi M. Combination Therapy with Dipeptidyl Peptidase-4 and P2X7 Purinoceptor Inhibitors Gives Rise to Antiepileptic Effects in Rats. J. Chem. Neuroanat. 2020;110:101855. doi: 10.1016/j.jchemneu.2020.101855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2020.101855</ArticleId><ArticleId IdType="pubmed">33031915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed N.H., Fathy N., Kortam M.A., Rabie M.A., Mohamed A.F., Kamel A.S. Vildagliptin Attenuates Huntington&#x2019;s Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. Neurother. J. Am. Soc. Exp. Neurother. 2020;17:252&#x2013;268. doi: 10.1007/s13311-019-00805-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00805-5</ArticleId><ArticleId IdType="pmc">PMC7007456</ArticleId><ArticleId IdType="pubmed">31728850</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., De Meester I., Verkerk R., De Medts P., Wauters A., Vanhoof G., Vandoolaeghe E., Neels H., Scharp&#xe9; S. Lower Serum Dipeptidyl Peptidase IV Activity in Treatment Resistant Major Depression: Relationships with Immune-Inflammatory Markers. Psychoneuroendocrinology. 1997;22:65&#x2013;78. doi: 10.1016/S0306-4530(96)00040-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4530(96)00040-6</ArticleId><ArticleId IdType="pubmed">9149329</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeghate E. Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions. Curr. Med. Chem. 2008;15:1851&#x2013;1862. doi: 10.2174/092986708785133004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986708785133004</ArticleId><ArticleId IdType="pubmed">18691043</ArticleId></ArticleIdList></Reference><Reference><Citation>Erfani S., Khaksari M., Oryan S., Shamsaei N., Aboutaleb N., Nikbakht F., Jamali-raeufy N., Gorjipour F. Visfatin Reduces Hippocampal CA1 Cells Death and Improves Learning and Memory Deficits after Transient Global Ischemia/Reperfusion. Neuropeptides. 2015;49:63&#x2013;68. doi: 10.1016/j.npep.2014.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2014.12.004</ArticleId><ArticleId IdType="pubmed">25617953</ArticleId></ArticleIdList></Reference><Reference><Citation>Park B.S., Jin S.H., Park J.J., Park J.W., Namgoong I.S., Kim Y.I., Lee B.J., Kim J.G. Visfatin Induces Sickness Responses in the Brain. PLoS ONE. 2011;6:e15981. doi: 10.1371/journal.pone.0015981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015981</ArticleId><ArticleId IdType="pmc">PMC3024312</ArticleId><ArticleId IdType="pubmed">21283791</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Miao Z., Jiang J., Yuan S., Fang W., Li B., Chen Y. Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2. Int. J. Mol. Sci. 2015;16:11439&#x2013;11451. doi: 10.3390/ijms160511439.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160511439</ArticleId><ArticleId IdType="pmc">PMC4463709</ArticleId><ArticleId IdType="pubmed">25993304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Weng J.-F., Hong W.-C., Luo L.-F., Yu W., Luo S.-D. Change in Plasma Visfatin Level after Severe Traumatic Brain Injury. Peptides. 2012;38:8&#x2013;12. doi: 10.1016/j.peptides.2012.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2012.08.016</ArticleId><ArticleId IdType="pubmed">22960047</ArticleId></ArticleIdList></Reference><Reference><Citation>Acik V., Matyar S., Arslan A., &#x130;stemen &#x130;., Olguner S.K., Arslan B., Gezercan Y., &#xd6;kten A.&#x130;. Relationsh&#x131;p of Spontaneous Subarachnoid Haemorrhage and Cerebral Aneurysm to Serum Visfatin and Nesfatin-1 Levels. Clin. Neurol. Neurosurg. 2020;194:105837. doi: 10.1016/j.clineuro.2020.105837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2020.105837</ArticleId><ArticleId IdType="pubmed">32311618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-N., Xu T.-Y., Li W.-L., Miao C.-Y. Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis. CNS Neurosci. Ther. 2016;22:431&#x2013;439. doi: 10.1111/cns.12539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12539</ArticleId><ArticleId IdType="pmc">PMC6492912</ArticleId><ArticleId IdType="pubmed">27018006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Liu X.-Z., Tian W.-W., Guan Y.-F., Wang P., Miao C.-Y. Extracellular Visfatin Has Nicotinamide Phosphoribosyltransferase Enzymatic Activity and Is Neuroprotective against Ischemic Injury. CNS Neurosci. Ther. 2014;20:539&#x2013;547. doi: 10.1111/cns.12273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12273</ArticleId><ArticleId IdType="pmc">PMC6493111</ArticleId><ArticleId IdType="pubmed">24750959</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H.-H., Chang J.C.-Y., Liu H.-C., Yang Z.-Y., Yang Y.-J., Chen L.-K., Yen D.H.-T. Handgrip Strength, Tumor Necrosis Factor-&#x3b1;, Interlukin-6, and Visfatin Levels in Oldest Elderly Patients with Cognitive Impairment. Exp. Gerontol. 2020;142:111138. doi: 10.1016/j.exger.2020.111138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2020.111138</ArticleId><ArticleId IdType="pubmed">33122129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>